Decoding 6 Analyst Evaluations For Viridian Therapeutics
Decoding 6 Analyst Evaluations For Viridian Therapeutics
解讀Viridian Therapeutics的6位分析師評估
Ratings for Viridian Therapeutics (NASDAQ:VRDN) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
在過去的三個月中，有6位分析師爲Viridian Therapeutics（納斯達克: VRDN）進行了評級，顯示了一些看好和看淡的觀點。
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
下表提供了他們最近的評級快照，展示了情緒在過去30天中的演變情況，並將其與之前的月份進行比較。
Insights from analysts' 12-month price targets are revealed, presenting an average target of $29.5, a high estimate of $42.00, and a low estimate of $23.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 6.05%.
分析師在12個月的價格目標中提供了見解，呈現出平均目標爲29.5美元，高估值爲42.00美元，低估值爲23.00美元。由於分析師將平均價格目標減少了6.05％，因此情緒發生了負向轉變。
Understanding Analyst Ratings: A Comprehensive Breakdown
分析師評級：全面解析
A clear picture of Viridian Therapeutics's...
通過對最近分析...
登入免費觀看全文
登入/註冊